Diabetes Mellitus, Type 2
Conditions
Keywords
Diabetes Mellitus, Type 2, Weight Loss, Financial Incentives, Hemoglobin A, Glycosylated
Brief summary
This feasibility study aims to compare the implementation process of three different interventions that use economic incentives to promote lifestyle behavioral changes in patients with type 2 diabetes mellitus, and to identify barriers and facilitators linked to the process of implementing each of the interventions. The interventions are based on economic incentives directed to the patient (individual incentives) or a team comprised by the patient and a partner (mixed incentives). Design: Three-month randomized control feasibility study to test the feasibility of implementing three types of intervention with economic incentives in patients with diabetes mellitus. Setting: Diabetes outpatient clinics from a public hospital in Peru.
Detailed description
Economic incentives have been used to promote changes in habits such as smoking and weight loss. However, no studies have been done to determine the impact of this strategy on the management of type 2 diabetes mellitus (T2DM). Additionally, previous studies do not describe ways to determine the amount of an economic incentive to promote behavioral changes, e.g adherence to treatment, increased physical activity and adherence to a healthy diet. There are also questions regarding the frequency of incentives, the type of incentive (cash or other prizes), and the preferred payment method that this study will allow us to explore. Furthermore, we want to test whether a team work approach (mixed incentives) vs. an individual approach (individual incentives) can also play a role in introducing behavioral changes. The goal of the study is to learn about the implementation process of three different interventions that use economic incentives to promote behavioral changes in patients with T2DM, and identify main barriers and facilitators tied to the implementation process of each intervention. This feasibility study will provide key insights to inform a future larger study; specifically, we will * Learn about the experience of participants with T2DM with economic incentives. * Learn about the experience of the companion/team support partners of the participants with T2DM. * Evaluate the patient's receptiveness to and comprehension of the educational materials used to promote behavioral changes. * Evaluate the patient and the companion/team support partner's receptiveness towards the received economic incentive as a tool for promoting behavioral changes. * Explore the companion/team support partner's activities that are most effective in helping with T2DM management of patients. * Explore whether patients with T2DM are able to keep a daily record of their efforts to manage their diabetes. * Evaluate the feasibility of packaging and implementing a future clinical trial that evaluates the impact of the use of economic incentives and teamwork in people with T2DM. From a clinical perspective, we will evaluate the feasibility of reaching the proposed clinical goals in terms of weight loss and HbA1c levels after the intervention period. Interventions Diabetes education (all arms). In the introductory meeting, a diabetes educator will explain to the participants all the procedures, including details of the number of sessions, and the participant's received a manual with information about diabetes management with a tailored weight loss plan. Each participant will be offered up to seven follow- up sessions with the diabetes educator, every two weeks, plus a final session, thus totaling up to 9 one-to-one interactions during the trial, provided that the participant attended all of their meetings. Participants will also be provided with a logbook to register their efforts regarding introducing changes in diet and physical activity. The information from this logbook will provide the starting point for conversations with the diabetes educator during the follow-up sessions, every two weeks. Goal setting (all arms). To determine eligibility for a cash reward, three goals were pre-specified: (1) Weight loss, 80 PEN if the participant loses one kilogram over a period of two weeks, (2) HbA1c level, 200 PEN if the participant achieves, at the end of the study, a decrease in 1% compared to their baseline level, and (3) HbA1c level and control, 400 PEN if the participant achieves, at the end of the study, a decrease ≥1% of A1c or reaches levels of A1c ≤6.5% compared to their baseline level. At the end of the study, targets for weight loss and HbA1c were evaluated independently, i.e. participants could receive more than one reward provided that each independent target was achieved. Companion/team support (Arm 2 and Arm 3). A companion/team support for each participant also receives information about diabetes care in the initial session and a brochure to guide and support the treatment process of the participant. The activities of the companion/team support member will be recorded, and they will be offered to join the follow- up sessions with the patient, every two weeks, but these will not be compulsory. Cash rewards. Two types of rewards will be considered. (1) Individual rewards (Arm 1 and Arm 2), the reward will be provided to the participant. If the participant were to have a companion/team support partner, the cash reward was given to the participant and no rules about sharing the reward (or not) with their companion/team support are established. (2) Shared rewards (Arm 3), i.e. the participant and their companion/team support will receive 50% of the cash reward each.
Interventions
Participants interact with a diabetes educator (DE), every two weeks.
Goals for weight loss and change in levels of HbA1c
Patient has a companion/team support partner to support achieving goals.
The cash reward is given to the patient with diabetes.
Patients with diabetes and their companion support will each receive 50% of the cash reward.
Sponsors
Study design
Eligibility
Inclusion criteria
for participants: * Type 2 diabetes mellitus * Body mass index 25-39.9 kg/m2, irrespective of HbA1c status * Able to give consent
Exclusion criteria
for participants: * Diagnosis of cancer or another serious comorbidity * Pharmacotherapy for weight loss or corticosteroids * Pregnant women * Blindness, amputation, foot ulcer or being on dialysis * Be companion/team support for another participant in the trial Inclusion criteria for the companion/team support: * Available and committed to supporting the participant in achieving their goals * Able to provide consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Glycated Hemoglobin | Baseline and 3 months | HbA1c change at 3 months from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Weight | Baseline and 3 months | Weight change at 3 months from baseline |
Countries
Peru
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Individual Incentives - Arm 1 This arm receives diabetes education + goal setting + individual rewards
Diabetes education: Participants interact with a diabetes educator (DE), every two weeks.
Goal setting: Goals for weight loss and change in levels of HbA1c
Individual Reward: The cash reward is given to the patient with diabetes. | 18 |
| Mixed Incentives (Altruism) - Arm 2 Patients This arm receives diabetes education + goal setting + companion support + individual rewards
Diabetes education: Participants interact with a diabetes educator (DE), every two weeks.
Goal setting: Goals for weight loss and change in levels of HbA1c
Companion Support: Patient has a companion/team support partner to support achieving goals.
Individual Reward: The cash reward is given to the patient with diabetes. | 18 |
| Mixed Incentives (Altruism) - Arm 2 Companions The companion support help the partner to achieve goals.
The cash reward is given to the patient with diabetes and not to the companion. | 18 |
| Mixed Incentives (Cooperation) - Arm 3 Patient This arm receives diabetes education + goal setting + companion support + shared rewards
Diabetes education: Participants interact with a diabetes educator (DE), every two weeks.
Goal setting: Goals for weight loss and change in levels of HbA1c
Companion Support: Patient has a companion/team support partner to support achieving goals.
Shared Reward: Patients with diabetes and their companion support will each receive 50% of the cash reward. | 18 |
| Mixed Incentives (Cooperation) - Arm 3 Companion The companion support help the partner to achieve goals.
Patients with diabetes and their companion support will each receive 50% of the cash reward. | 18 |
| Total | 90 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 3 | 4 | 5 | 3 | 4 |
Baseline characteristics
| Characteristic | Individual Incentives - Arm 1 | Mixed Incentives (Altruism) - Arm 2 Patients | Mixed Incentives (Altruism) - Arm 2 Companions | Mixed Incentives (Cooperation) - Arm 3 Patient | Mixed Incentives (Cooperation) - Arm 3 Companion | Total |
|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 2 Participants | 3 Participants | 2 Participants | 0 Participants | 9 Participants |
| Age, Categorical Between 18 and 65 years | 16 Participants | 16 Participants | 15 Participants | 16 Participants | 18 Participants | 81 Participants |
| Age, Continuous | 54.7 years STANDARD_DEVIATION 9.8 | 55.5 years STANDARD_DEVIATION 9.8 | 49.8 years STANDARD_DEVIATION 15.9 | 54.2 years STANDARD_DEVIATION 7.6 | 39.7 years STANDARD_DEVIATION 16.6 | 54.4 years STANDARD_DEVIATION 9 |
| Glycated Hemoglobin | 8.5 Percentage of glycated hemoglobin STANDARD_DEVIATION 2.2 | 7.9 Percentage of glycated hemoglobin STANDARD_DEVIATION 3.1 | — | 8.2 Percentage of glycated hemoglobin STANDARD_DEVIATION 2.1 | — | 8.2 Percentage of glycated hemoglobin STANDARD_DEVIATION 2.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 18 Participants | 18 Participants | 18 Participants | 18 Participants | 18 Participants | 90 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Peru | 18 Participants | 18 Participants | 18 Participants | 18 Participants | 18 Participants | 90 Participants |
| Sex: Female, Male Female | 12 Participants | 12 Participants | 11 Participants | 12 Participants | 11 Participants | 58 Participants |
| Sex: Female, Male Male | 6 Participants | 6 Participants | 7 Participants | 6 Participants | 7 Participants | 32 Participants |
| Weight | 76.9 Kg STANDARD_DEVIATION 10.7 | 84.5 Kg STANDARD_DEVIATION 17.4 | — | 85.1 Kg STANDARD_DEVIATION 22.3 | — | 82.1 Kg STANDARD_DEVIATION 17.5 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 18 | 0 / 18 | 0 / 18 |
| other Total, other adverse events | 0 / 18 | 0 / 18 | 0 / 18 |
| serious Total, serious adverse events | 0 / 18 | 0 / 18 | 0 / 18 |
Outcome results
Change in Glycated Hemoglobin
HbA1c change at 3 months from baseline
Time frame: Baseline and 3 months
Population: Some participants had data about weight but not about glycated hemoglobin and for that reason the number of participants in this table are different from the table that show the results of weight.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Individual Incentives - Arm 1 | Change in Glycated Hemoglobin | 1.4 Percentage of glycated hemoglobin | Standard Deviation 1.4 |
| Mixed Incentives (Altruism) - Arm 2 | Change in Glycated Hemoglobin | 0.9 Percentage of glycated hemoglobin | Standard Deviation 1.2 |
| Mixed Incentives (Cooperation) - Arm 3 | Change in Glycated Hemoglobin | 1.1 Percentage of glycated hemoglobin | Standard Deviation 1.6 |
Change in Weight
Weight change at 3 months from baseline
Time frame: Baseline and 3 months
Population: Some participants had data about weight but not about glycated hemoglobin and for that reason the number of participants in this table are different from the table that show the results of glycated hemoglobin.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Individual Incentives - Arm 1 | Change in Weight | 2.9 Kg | Standard Deviation 2.2 |
| Mixed Incentives (Altruism) - Arm 2 | Change in Weight | 0.4 Kg | Standard Deviation 2.5 |
| Mixed Incentives (Cooperation) - Arm 3 | Change in Weight | 0.4 Kg | Standard Deviation 3 |